02:45 PM EST, 12/20/2024 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said Friday the US Food and Drug Administration has approved an expanded indication for IMCIVREE to include children as young as 2 years old.

The drug is indicated to lower excess body weight and keep weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome or genetically confirmed pro-opiomelanocortin.

Rhythm shares were up more than 2% in recent trading.

Price: 56.65, Change: +1.17, Percent Change: +2.11